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Perioperative cisplatin-based combination chemotherapy 
is a first-line treatment strategy for muscle-invasive 
bladder cancer (MIBC) patients with or without metastasis. 
According to current European Association of Urology 
(EAU) guidelines, the use of neoadjuvant chemotherapy 
(NAC) is strongly recommended to patients with clinical 
T2–T4a and N0M0 disease (1). However, existing data 
show that NAC provides only an 8% absolute survival 
benefit at five years, which means that 12 patients have to be 
treated with NAC to avoid one death in five years (2). This 
demonstrates that only a smaller group of patients benefit 
from NAC treatment. This survival benefit is restricted 
to pathological responders, who show partial or complete 
response. In addition, novel effective immunotherapy 
agents are now available for cisplatin resistant and cisplatin 
ineligible MIBC patients. Therefore, there is an urgent and 
unmet need for biomarkers in order to predict response to 
cisplatin chemotherapy.
In their study Pietzak et al. divided patients into groups of 
“primary” MIBC (patients who had MIBC at first diagnosis) 
and “secondary” MIBC (who were diagnosed with a non-
muscle invasive bladder cancer and progressed to MIBC) 
and found that secondary MIBC patients experienced lower 
survival rates after NAC treatment compared to patients 
with primary MIBC (3). In addition, they demonstrated 
that patients that do not exhibit a pathologic response to 
NAC had inferior survival rates compared to patients who 
were only treated by radical cystectomy without NAC. This 
suggests that patients who are not responsive to cisplatin 
have a better chance of survival with upfront cystectomy 
without NAC. This observation is important and further 
highlights the need for prediction of cisplatin therapy.
Urinary bladder cancer in most cases manifests as 
urothelial carcinoma which is a heterogeneous disease 
regarding its morphological and histological appearance 
as well as its clinical behavior. About 70% of BCs are non-
muscle-invasive (NMIBC) at first presentation, while 30% 
of patients already have muscle-invasive disease (MIBC). 
These two groups of patients show characteristic differences 
regarding their clinical behavior as well as morphological, 
histological and molecular features. NMIBC patients are 
usually treated with transurethral resection and have an 
excellent prognosis with a survival rate of over 90% after 
five years. NMIBCs often recur but rarely progress. In 
contrast, MIBC patients have a survival rate of only 50% 
after five years. MIBC patients are usually treated with 
radical cystectomy and perioperative, adjuvant or NAC. 
NMIBCs mostly appear as papillary disease while MIBC 
predominantly shows higher tumor burden and in almost 
all cases a high-grade morphology with more solid growth 
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patterns [for the usual/not-otherwise specified (NOS) type] 
or variant differentiation as for example micropapillary, 
squamous or plasmacytoid patterns which can be detected 
in up to one third of cases and are associated with 
worse outcome (4). The fact that NMIBCs relatively 
rarely progress to MIBC suggests different molecular 
pathomechanisms for these two clinically different patient 
groups. Early studies identified typical genetic alterations 
for NMIBC which are less frequently present in MIBC 
further confirming the different nature of these tumors. 
NMIBCs show an overall lower mutational load with high 
frequencies of 9p chromosomal deletion (CDKN2A loss) as 
well as FGFR3 and HRAS alterations. In contrast, MIBC 
exhibit a high rate of genetic instability with abundant TP53 
and RB1 mutations but less frequent FGFR3 and CDKN2A 
alterations (5).
In the last few years high throughput sequencing and 
gene expression analyses provided a never before seen 
insight into the molecular background of cancer. In bladder 
cancer, hierarchical cluster analyses of gene expression 
data distinguished different molecular subtypes in muscle-
invasive urothelial cancer, as for example the “luminal” and 
“basal” subtypes which were named after their parallels in 
breast cancer (6,7). Basal tumors can be characterized by 
high expressions of mesenchymal markers and EGFR, while 
luminal bladder cancers typically express epithelial markers 
and show higher FGFR3 alteration rates (7). In addition, a 
“p53-like” subtype has been distinguished with both luminal 
and basal gene expressions and a gene signature activated 
by wild-type p53. However, a later immunohistochemical 
study revealed that the characteristic p53-like markers 
were almost exclusively expressed in the stromal cells 
(fibroblasts, smooth muscle cells, immune cells) but not in 
the cancer cells themselves. Therefore, the p53-like gene 
signature is most probably a result of stromal contamination 
and therefore does not represent an intrinsic subtype of 
bladder cancer (8). In further analyses, the The Cancer 
Genome Atlas (TCGA) consortium comprehensively 
analyzed the molecular background of 412 MIBCs (9). 
This study supported the existence of luminal and basal 
subtypes and additionally identified the smaller subgroup 
of “neuroendocrine-like” tumors with a very unfavorable 
prognosis.  Furthermore, the luminal subtype was 
subdivided into “luminal papillary”, “luminal infiltrated” 
and “luminal” groups. Based on molecular features both 
at the DNA and RNA level, the luminal papillary subtype 
shows the highest similarity to NMIBC, which suggests 
that tumors progressed from NMIBCs are enriched in the 
luminal papillary subtype. According to a large study on 
MIBC patients with or without NAC treatment, none of 
the luminal subtypes benefited from chemotherapy and 
only MIBC patients with basal molecular subtype gained 
any survival benefit from NAC (10). In addition, Pietzak 
and co-workers in the present study found that patients 
with secondary MIBC have lower radiographic response 
rates and shorter survival compared to primary MIBC, 
suggesting that secondary MIBC patients are more likely 
to be chemotherapy-resistant (3). Against this background, 
it seems plausible that the secondary MIBCs in Pietzak’s 
study mainly resemble tumors of the luminal subtypes—
most probably the luminal papillary subtype—which is 
known to be cisplatin-resistant. However, in their study 
the authors state that their primary and secondary groups 
did not overlap with molecular subtypes when analyzed 
in the discovery cohort. Comparing the mutation pattern 
between Pietzak’s primary and secondary MIBC groups in 
the validation cohort, we may have observed differences 
between typically affected genes. TP53 and RB1 mutations—
which are known to be enriched in basal subtype - are more 
frequent in primary MIBC (42% vs. 69% for TP53, 17% vs. 
31% for RB1) while CDKN2A and FGFR3 alterations which 
are known to be more abundant in the luminal subtype 
were more frequent in secondary MIBC (17% vs. 25% for 
CDKN2A, and 7% vs. 25% for FGFR3). Interestingly, when 
mutational frequencies are considered in the combined 
cohort (including both the retrospective discovery and 
prospective validation cohort), these characteristic 
differences in mutational frequencies disappeared. These 
marked differences in the mutation frequencies between the 
two cohorts may challenge the representative nature of the 
discovery cohort and might explain the lacking difference 
in the distribution of molecular subtypes between the 
primary versus secondary MIBC in the discovery cohort. 
As molecular subtypes as such have not been assessed in 
the prospective validation cohort, we cannot exclude a 
possible association of molecular subtypes with primary 
and secondary MIBC. Based on these, in our opinion 
the difference of NAC sensitivity between primary and 
secondary MIBC may be related to their different intrinsic 
molecular subtype. If so, dichotomization into primary and 
secondary MIBC might be used as a surrogate/indicative 
marker for the classification into luminal and basal subtypes 
and therefore might be used to predict cisplatin-sensitivity 
in bladder cancer. This would be of great clinical relevance 
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as current subtype classifications are based on transcriptome 
sequencing with the parallel consideration of mRNA 
expressions of >3,000 genes which in its present form is too 
complex for routine clinical use.
In further large-scale cancer characterization efforts, 
the so-called pan-cancer analyses aim to compare genomic 
and cellular alterations across various tumors, which 
allows for the observation of fundamental differences and 
similarities between distinct tumor entities. This approach 
has allowed deciphering the patterns of somatic mutations 
caused by different mutational processes and resulted in 
the identification of 30 validated mutational signatures. 
The etiology of some of these mutational signatures has 
already been attributed to endogenous or exogenous 
mutagenic processes. There are mutational signatures 
found to be associated with exposures to ultraviolet 
(UV) light, aflatoxin, aristolochic acid, alkylating agents 
or tobacco smoking while others are associated with 
impaired mismatch or double-strand-break repair 
functions. In accordance, a mutational signature related 
to UV exposure was observed in malignant melanoma and 
mutational signatures associated to tobacco smoking were 
found in lung cancer. Surprisingly, despite smoking is 
known to be a significant risk factor for urothelial bladder 
cancer, typical smoking-related mutational signatures 
were not found in MIBC. On the other hand, according 
to the results of the TCGA II study on bladder cancer, 
ERCC2-related mutations were characteristic for one of 
the four mutational signature groups found in MIBC. In 
addition, the frequency of ERCC2 signature mutations was 
associated with smoking, suggesting that smoking may 
influence the mutational landscape of bladder cancer by 
provoking an ERCC2-related mutational pattern (9). In the 
study of Pietzak et al., ERCC2 mutations were significantly 
enriched in patients with primary compared to secondary 
MIBC (17% vs. 0%). ERCC2 (ERCC Excision Repair 2, 
TFIIH Core Complex Helicase Subunit) is known to play 
a role in the nucleotide excision repair (NER) pathway. 
Chemotherapy agents such as cisplatin disrupt the DNA 
structure, which is recognized and repaired by the NER 
system. Urothelial cancer carries somatic mutation of 
ERCC2 gene with a relative high frequency of 6–18%.
The ERCC2 genetic alterations have formerly found 
to be associated with therapeutic response to NAC (11). 
Van Allen et al. performed whole-exome sequencing in 50 
NAC treated MIBC patients (25 responders vs. 25 non-
responders) in order to identify somatic mutations that 
occur preferentially in responders. ERCC2 inactivating 
mutations were found to be the only genetic alterations to 
be significantly enriched in responders (35% in responders 
vs. 0% in non-responders). These results could be validated 
in a similar sized independent validation cohort showing 
ERCC2 mutations in 40% of responders compared to 
7% of non-responders (12). Pietzak and co-worker’s 
results indirectly support the predictive role of ERCC2 
in cisplatin therapy as its mutations were significantly 
enriched in primary MIBC patients who had a better 
response to chemotherapy compared to secondary MIBC. 
In contrast, Gronendijk et al. found ERCC2 mutations in 
16% of responders compared to 6% of non-responders 
which did not reach the significance level (13). In a 
further discussion of these conflicting results, it has been 
highlighted that the two ERCC2 mutant and non-responder 
patients received carboplatin and not cisplatin which may 
account for discrepant findings (12,14). Recent functional 
analyses demonstrated that nearly all clinically observed 
ERCC2 missense mutations were able to attenuate normal 
cellular NER and consequently increase sensitivity to 
cisplatin (15). In summary, ERCC2 alterations are associated 
with smoking, they are more common in primary MIBC and 
they are clearly associated with a better response to cisplatin 
therapy. Therefore, ERCC2 may be a valuable marker for 
the prediction of NAC efficacy in MIBC, however, it seems 
to have a high positive predictive value but low negative 
predictive value meaning that an ERCC2 test could identify 
potential responders with a high reliability but at the 
same time would miss a relative high number of potential 
responders. Therefore, testing of ERCC2 status may be used 
in combination with other markers rather than alone to select 
MIBC patients potentially eligible for cisplatin therapy. 
In conclusion, current changes in the therapeutic 
landscape of bladder cancer call for methods of efficacy 
prediction of perioperative cisplatin-based chemotherapy 
in order to guide therapy decisions in a more individualized 
manner. The study of Pietzak and co-workers shows that 
the two groups of MIBC and molecular patterns are linked 
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